Please login to the form below

Not currently logged in
Email:
Password:

Lonza

This page shows the latest Lonza news and features for those working in and with pharma, biotech and healthcare.

KaloBios files for bankruptcy protection

KaloBios files for bankruptcy protection

Miami and a number of contractors including Lonza, Catalent, INC Research and PPD.

Latest news

  • BMS expand biologics manufacturing deal with Lonza BMS expand biologics manufacturing deal with Lonza

    Bristol-Myers Squibb and Lonza have entered a multi-year expansion of their existing biologics manufacturing agreement. ... BMS and Lonza have been collaborating since 2003 to produce commercial supplies of biologics medicine marketed by BMS worldwide.

  • AbbVie unveils its first Asian manufacturing plant AbbVie unveils its first Asian manufacturing plant

    Aside from AbbVie, companies such as GlaxoSmithKline, Lonza, Merck &Co, Novartis, Pfizer and Sanofi have all chosen to locate manufacturing facilities in Singapore, and the headcount in the country's biomedical

  • DSM merges pharma unit with Patheon DSM merges pharma unit with Patheon

    Patheon after beating out Lonza in a bidding war in 2009.

  • Baxter taps Coherus for Enbrel biosimilar Baxter taps Coherus for Enbrel biosimilar

    It also comes shortly after Teva and Lonza dissolved their biosimilar partnership, blaming the high level of investment required and the regulatory complexity of bringing them to market, although market research

  • Lonza ends biosimilars deal with Teva Lonza ends biosimilars deal with Teva

    Chemical firm cuts losses after four-year development deal.  . Teva and Lonza have agreed to terminate a deal to develop a series of biologics, including biosimilars. ... In the chemical company's second quarter financial statement, Lonza said it made

More from news
Approximately 2 fully matching, plus 9 partially matching documents found.

Latest Intelligence

  • Cell and gene therapy Cell and gene therapy

    Lonza has worked with 150 cell and gene therapy developers and each project has required a different approach, Hong added. ... As a result, Lonza’s efforts to reduce cell and gene therapy production costs involve logistics, said Hong.

  • Deal Watch February 2017 Deal Watch February 2017

    Licence. 320. Lonza/ Sanofi. Large scale mammalian cell manufacturing facility for antibody therapeutics.

  • Deal Watch December 2016 Deal Watch December 2016

    Headline $m. Capsugel (US). Lonza (Switzerland). Acquisition. Oral delivery technologies, development, formulation and manufacturing for pharma, consumer and nutrition products. ... LifeCell. Allergan. 12.3%. Vascular Solutions. Teleflex. 8.8%. Capsugel.

  • Biosimilars in China Biosimilars in China

    Several joint venture deals between MNCs and Chinese players have been sealed recently: Hisun with Pfizer, Simcere with Merck and Fosun with Lonza.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
JPA Health Communications

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

Patient journey mapping: exploring the clinical and the emotional journey
By Chris Hodgson, Neil Rees, Sumira Riaz and Karen Petticrew While we can all agree that the value of developing a patient journey map cannot be underestimated when exploring the...
Precision medicine at Blue Latitude Health
At Blue Latitude Health we have identified 90+ insights about commercialising precision medicines. Check out our video to get a run down on three core components of the commercialisation and...
Understanding the evolving CAR-T market
In 2017 the approval of the first CAR-T treatment took the world by storm, transforming the way cancer is treated, but two years later more than 500 CAR-Ts are in...

Infographics